(NASDAQ: MIRM) Mirum Pharmaceuticals's forecast annual revenue growth rate of 18.64% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.31%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.91%.
Mirum Pharmaceuticals's revenue in 2026 is $618,067,000.On average, 14 Wall Street analysts forecast MIRM's revenue for 2026 to be $46,174,588,197, with the lowest MIRM revenue forecast at $43,605,870,247, and the highest MIRM revenue forecast at $48,093,334,796. On average, 14 Wall Street analysts forecast MIRM's revenue for 2027 to be $54,041,124,591, with the lowest MIRM revenue forecast at $47,740,103,612, and the highest MIRM revenue forecast at $60,140,855,741.
In 2028, MIRM is forecast to generate $68,308,677,556 in revenue, with the lowest revenue forecast at $58,431,840,158 and the highest revenue forecast at $77,983,575,803.